PSTV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Plus Therapeutics Inc (PSTV) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has promising developments in its pipeline, the financial performance is weak, and the stock lacks immediate positive trading signals. It is better to monitor the stock for further developments or improved financial metrics before making a purchase.
The MACD is positive and expanding, suggesting a bullish momentum. However, RSI is neutral at 78.074, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 0.297, with resistance at 0.332 and support at 0.262.
The American Medical Association's approval of a CPT code for REYOBIQ enhances market access.
Clinical trials are supported by significant grants, including $17.6 million from the Cancer Prevention & Research Institute of Texas.
The company is advancing its Phase 2 recurrent glioblastoma trial, with a catalyst-rich 2026 expected.
Recent equity dilution has led to lowered price targets by analysts.
Financial performance shows declining revenue (-4.05% YoY) and EPS (-89.19% YoY), despite improved net income.
Pre-market price is down by -1.73%, showing weak short-term sentiment.
In Q3 2025, revenue dropped by 4.05% YoY to $1,397,000. Net income improved by 53.90% YoY to -$4,423,000, but EPS declined significantly by 89.19% YoY to -0.04. Gross margin remained stable at 100%.
Analysts maintain a Buy rating despite lowering price targets due to equity dilution. The stock has a price target range of $1 to $2, with expectations of a catalyst-rich 2026 driven by clinical trial advancements.
